Respiratory syncytial virus (RSV) is the most important cause of severe lower respiratory tract illness in infants and the elderly. Currently, no safe and efficacious RSV vaccine exists. Advances in our understanding of immunity and disease pathogenesis associated with infection have shown that RSV G protein contains a CX3C chemokine motif that interacts with the CX3CR1 chemokine receptor, modifies the activities of CX3CL1, and affects aspects of immunity and disease pathogenesis. Antibodies directed to the CX3C motif inhibit G protein CX3C-CX3CR1 interaction and reduce disease pathogenesis. The long- term goal of our research is to develop a novel nanocapsule vaccine engineered to carry a RSV G protein polypeptide that we have previously shown to induce neutralizing and disease protective antibody. The nanocapsule technology is attractive for vaccine development as it targets professional antigen- presenting cells which we have shown to improve the immunogenicity of both T cell and antibody target epitopes. The proposal will take advantage of well-defined assays and a mouse model to: (1) Identify the optimal CX3C motif vaccine antigen sequence based on G polypeptide vaccination of mice and evaluation of G protein CX3C-CX3CR1 blocking antibody responses, (2) Construct nanocapsule vaccine candidates with the appropriate G polypeptide and demonstrate immunogenicity and protection in a mouse model, (3) Use optimized, efficacious nanocapsule vaccines to further understand the disease modifying effect of antibodies that block G protein CX3C-CX3CR1 interaction and disease pathogenesis, 4) Evaluate parameters of safety and duration of vaccine efficacy in the memory response to (G peptide nanocapsule vaccination and RSV challenge, and (5) Evaluate the safety and efficacy of G peptide nanocapsule vaccine in the context of pre-existing RSV immunity. The proposed research is innovative because it will identify regions in the RSV G protein that induce antibodies which neutralize infection and block RSV disease, incorporate the optimal polypeptide in an novel nanocapsule-based vaccine candidate that targets antigen-presenting cells, and will provide long-term protection against RSV strains. Respiratory syncytial virus is the most important cause of sever lower respiratory tract illness in infants and the elderly. Currently, no safe and efficacious RSV vaccine exists. The long-term goal of our research is to develop a novel nanocapsule vaccine engineered to carry a RSV G protein polypeptide that we have previously shown to induce neutralizing and disease protective antibody.

Public Health Relevance

Respiratory syncytial virus (RSV) is the most important cause of sever lower respiratory tract illness in infants and the elderly. Currently, no safe and efficacious RSV vaccine exists. The long-term goal of our research is to develop a novel nanocapsule vaccine engineered to carry a RSV G protein polypeptide that we have previously shown to induce neutralizing and disease protective antibody.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI088744-04
Application #
8450155
Study Section
Special Emphasis Panel (ZAI1-TS-M (J1))
Program Officer
Kim, Sonnie
Project Start
2010-04-01
Project End
2015-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
4
Fiscal Year
2013
Total Cost
$528,153
Indirect Cost
$125,339
Name
University of Georgia
Department
Microbiology/Immun/Virology
Type
Schools of Veterinary Medicine
DUNS #
004315578
City
Athens
State
GA
Country
United States
Zip Code
30602
Jorquera, Patricia A; Choi, Youngjoo; Oakley, Katie E et al. (2013) Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease. PLoS One 8:e74905
Boyoglu-Barnum, Seyhan; Gaston, Kelsey A; Todd, Sean O et al. (2013) A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice. J Virol 87:10955-67
Choi, Youngjoo; Mason, Caleb S; Jones, Les P et al. (2012) Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains. Viral Immunol 25:193-203
Caidi, Hayat; Harcourt, Jennifer L; Tripp, Ralph A et al. (2012) Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice. PLoS One 7:e51485
Radu, Gertrud U; Caidi, Hayat; Miao, Congrong et al. (2010) Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice. J Virol 84:9632-6
Oshansky, Christine M; Barber, James P; Crabtree, Jackelyn et al. (2010) Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells. J Infect Dis 201:1201-7
Zhang, Wenliang; Choi, Youngjoo; Haynes, Lia M et al. (2010) Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol 84:1148-57
Kauvar, Lawrence M; Harcourt, Jennifer L; Haynes, Lia M et al. (2010) Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy 2:655-61